Direct comparative studies of different BTK inhibitors in anti-MAG neuropathy are limited, likely due to the novelty of this therapeutic approach. Zanubrutinib, a novel Bruton tyrosine kinase (BTK) inhibitor, has garnered considerable attention as a therapeutic agent for WM and anti-MAG neuropathy [24]. While zanubrutinib is being investigated in the MAGNAZ phase II trial for patients with MGUS and anti-MAG neuropathy, the results of this trial are still pending [25]. The gene discussed is BTK; the disease is neuropathy.